On February 3, 2009, Allos Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing the final results from the Company's pivotal Phase 2 PROPEL trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

(d) Exhibits

99.1    Press Release, dated February 3, 2009, entitled "Allos Therapeutics
        Announces Final Results From Pivotal Propel Trial Of Pralatrexate In
        Patients With Peripheral T-Cell Lymphoma."